调节性B细胞在自身免疫性溶血性贫血患者外周血中的表达及临床意义

目的: 探讨自身免疫性溶血性贫血（AIHA）患者外周血中调节性B细胞（Bregs）的表达及其在该病发病中的意义。方法:选择16例自身免疫性溶血性贫血患者和14例健康志愿者为研究对象，用流式细胞术分析外周血CD19+IL-10+调节性B细胞及CD19+CD24hiCD27+调节性B细胞的表达；ELISA方法检测培养上清液中IL-10的水平。结果:自身免疫性溶血性贫血患者外周血中CD19+IL-10+调节性B细胞、CD19+CD24hiCD27+调节性B细胞的表达分别为（1.27±0.39）％、（9.85±2.18）％，健康志愿者组分别为（2.92±0.71）％、（26.47±4.31）％，两组比较差异有统计学意义（P<0.05）；自身免疫性溶血性贫血患者细胞培养上清中IL-10的水平低于健康志愿者组（P<0.05）。结论:自身免疫性溶血性贫血患者外周血中CD19+IL-10+调节性B细胞及CD19+CD24hiCD27+调节性B细胞比例降低，提示调节性B细胞可能参与自身免疫性溶血性贫血的发病过程。     

IgGs-Abzymes from the Sera of Patients with Multiple Sclerosis Recognize and Hydrolyze miRNAs

Autoantibodies-abzymes hydrolyzing DNA, myelin basic protein, and oligosaccharides have been revealed in the sera of patients with multiple sclerosis (MS). In MS, specific microRNAs are found in blood and cerebrospinal fluid, which are characterized by increased expression. Autoantibodies, specifically hydrolyzing four different miRNAs, were first detected in the blood of schizophrenia patients. Here, we present the first evidence that 23 IgG antibodies of MS patients effectively recognize and hydrolyze four neuroregulatory miRNAs (miR-137, miR-9-5p, miR-219-2-3p, and miR-219-5p) and four immunoregulatory miRNAs (miR-21-3p, miR-146a-3p, miR-155-5p, and miR-326). Several known criteria were checked to show that the recognition and hydrolysis of miRNAs is an intrinsic property of MS IgGs. The hydrolysis of all miRNAs is mostly site-specific. The major and moderate sites of the hydrolysis of each miRNA for most of the IgG preparations coincided; however, some of them showed other specific sites of splitting. Several individual IgGs hydrolyzed some miRNAs almost nonspecifically at nearly all internucleoside bonds or demonstrated a combination of site-specific and nonspecific splitting. Maximum average relative activity (RA) was observed in the hydrolysis of miR-155-5p for IgGs of patients of two types of MS—clinically isolated syndrome and relapsing-remitting MS—but was also high for patients with primary progressive and secondary progressive MS. Differences between RAs of IgGs of four groups of MS patients and healthy donors were statistically significant (p < 0.015). There was a tendency of decreasing efficiency of hydrolysis of all eight miRNAs during remission compared with the exacerbation of the disease.     

Extracellular Vesicles Tune the Immune System in Renal Disease: A Focus on Systemic Lupus Erythematosus,Antiphospholipid Syndrome,Thrombotic Microangiopathy and ANCA-Vasculitis

Extracellular vesicles (EV) are microparticles released in biological fluids by different cell types, both in physiological and pathological conditions. Owing to their ability to carry and transfer biomolecules, EV are mediators of cell-to-cell communication and are involved in the pathogenesis of several diseases. The ability of EV to modulate the immune system, the coagulation cascade, the angiogenetic process, and to drive endothelial dysfunction plays a crucial role in the pathophysiology of both autoimmune and renal diseases. Recent studies have demonstrated the involvement of EV in the control of renal homeostasis by acting as intercellular signaling molecules, mediators of inflammation and tissue regeneration. Moreover, circulating EV and urinary EV secreted by renal cells have been investigated as potential early biomarkers of renal injury. In the present review, we discuss the recent findings on the involvement of EV in autoimmunity and in renal intercellular communication. We focused on EV-mediated interaction between the immune system and the kidney in autoimmune diseases displaying common renal damage, such as antiphospholipid syndrome, systemic lupus erythematosus, thrombotic microangiopathy, and vasculitis. Although further studies are needed to extend our knowledge on EV in renal pathology, a deeper investigation of the impact of EV in kidney autoimmune diseases may also provide insight into renal biological processes. Furthermore, EV may represent promising biomarkers of renal diseases with potential future applications as diagnostic and therapeutic tools.     

Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis

Multiple sclerosis is characterized by inflammatory demyelination and axonal loss as pathophysiological correlates of relapsing activity and progressive development of clinical disability. The molecular processes involved in this pathogenesis are still unclear as they are quite complex and heterogeneous. In this article we present protein expression analysis of brain and spinal cord tissues from different models of murine experimental autoimmune encephalomyelitis (EAE), the most commonly used animal model for multiple sclerosis. We observed a number of EAE-specific protein expression and PTM differences. Proteome analysis was extended to multiple sclerosis specimens in order to validate the EAE findings. Our findings suggest the regulation of a number of proteins that shed light on the molecular mechanisms of the disease processes taking place in EAE and multiple sclerosis. We found consistent modulation of proteins including serum amyloid P component, sirtuin 2, dihydropyrimidinase-related protein family proteins, stathmin 1, creatine kinase B and chloride intracellular channel protein 1. Functional classification of the proteins by database and the literature mining reveals their association with neuronal development and myelinogenesis, suggesting possible disease processes that mediate neurodegeneration.     

Antibody-Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases

Chronic inflammatory diseases are often progressive, resulting not only in physical damage to patients but also social and economic burdens, making early diagnosis of them critical. Nuclear medicine techniques can enhance the detection of inflammation by providing functional as well as anatomical information when combined with other modalities such as magnetic resonance imaging, computed tomography or ultrasonography. Although small molecules and peptides were mainly used for the treatment and imaging of chronic inflammatory diseases in the past, antibodies and their fragments have also been emerging for chronic inflammatory diseases as they show high specificity to their targets and can have various biological half-lives depending on how they are engineered. In addition, imaging with antibodies or their fragments can visualize the in vivo biodistribution of the probes or help monitor therapeutic responses, thereby providing physicians with a greater understanding of drug behavior in vivo and another means of monitoring their patients. In this review, we introduce various targets and radiolabeled antibody-based probes for the molecular imaging of chronic inflammatory diseases in preclinical and clinical studies. Targets can be classified into three different categories: 1) cell-adhesion molecules, 2) surface markers on immune cells, and 3) cytokines or enzymes. The limitations and future directions of using radiolabeled antibodies for imaging inflammatory diseases are also discussed.     

Immunoproteasome β5i‐Selective Dipeptidomimetic Inhibitors

N,C‐capped dipeptides belong to a class of noncovalent proteasome inhibitors. Herein we report that the insertion of a β‐amino acid into N,C‐capped dipeptides markedly decreases their inhibitory potency against human constitutive proteasome β5c, while maintaining potent inhibitory activity against human immunoproteasome β5i, thereby achieving thousands‐fold selectivity for β5i over β5c. Structure–activity relationship studies revealed that β5c does not tolerate the β‐amino acid based dipeptidomimetics as does β5i. In vitro, one such compound was found to inhibit human T cell proliferation. Compounds of this class may have potential as therapeutics for autoimmune and inflammatory diseases with less mechanism‐based cytotoxicity than agents that also inhibit the constitutive proteasome.     

腺苷A2AR拮抗剂对中枢炎症性小胶质细胞形态和功能的影响

目的:探讨腺苷A2A受体拮抗剂对实验性自身免疫性脑脊髓炎（EAE）的治疗作用及其对中枢炎症性小胶质细胞形态和功能的影响。方法:MOG35-55免疫诱导建立EAE模型,EAE小鼠出现神经功能缺损症状后开始腹腔注射腺苷A2AR拮抗剂至发病后第10天。ELISA法检测中枢神经系统内IFN-γ、IL-17、TGF-β、IL-10的表达情况,免疫荧光双重染色法检测小胶质细胞内M1型细胞标志物诱导型一氧化氮合酶（iNOS）和M2型细胞标志物精氨酸酶I（ArgI）的合成情况。离体培养BV-2小胶质细胞,LPS诱导的小胶质细胞炎症反应,并予A2AR拮抗剂干预,Real-time PCR和ELISA法检测M1型和M2型细胞相关的细胞因子RNA表达水平和分泌水平。Western Blot法检测各组小胶质细胞内M1型和M2型细胞标志物的表达量。结果:腺苷A2AR拮抗剂能有效缓解发病后EAE小鼠的神经功能缺损症状,降低IFN-γ的分泌水平,使M1型细胞相关的iNOS合成减少,M2型细胞相关的ArgI合成增多。腺苷A2AR拮抗剂能减少LPS刺激后BV-2小胶质细胞M1型细胞相关的细胞因子IL-1β的mRNA表达量和分泌量,对M2型细胞相关的细胞因子及蛋白无显著影响。结论:腺苷A2AR拮抗剂对发病后的EAE小鼠有肯定的治疗作用,其机制可能与改变中枢炎症过程中小胶质细胞的表型（M1/M2转换）改变（形态和功能）有关。     

转化生长因子-β在骨髓间充质干细胞治疗实验性自身免疫性重症肌无力机制中的作用

目的探讨转化生长因子-β(TGF-β)在骨髓间充质干细胞(BMSCs)治疗实验性自身免疫性重症肌无力(EAMG)机制中的作用。方法分离培养健康Lewis大鼠BMSCs,并进行大量体外扩增;以大鼠来源的乙酰胆碱受体(R-AChR)2次免疫Lewis大鼠,建立EAMG模型;第2次免疫的同时,经尾静脉移植BMSCs,1×107个/只,依据Lennon评分标准,进行体重测量和临床体征评定。并通过体外实验进一步探讨TGF-β在治疗EAMG过程中的具体机制。结果BMSCs移植明显缓解了EAMG的临床症状,临床评分及体重变化差异均有统计学意义,表明治疗有效;体外实验结果显示,BMSCs能通过TGF-β的分泌影响AChR特异性Th17/Treg细胞亚群的分布及其相关因子的分泌,以anti-TGF-β抗体封闭后,这种调节作用在一定程度上被抑制。结论BMSCs通过细胞因子TGF-β,能在一定程度上调节AChR特异性Th17/Treg细胞亚群的平衡,从而起到治疗EAMG的作用。